Case T-329/16: Judgment of the General Court of 5 December 2018 — Bristol-Myers Squibb Pharma v Commission and EMA (Medicinal products for human use — Orphan medicinal products — Decision withdrawing the designation of Elotuzumab as an orphan medicinal product — Decision that the designation criteria were no longer met — Marketing authorisation for the medicinal product for human use Empliciti (Elotuzumab) — Article 5(12)(b) of Regulation (EC) No 141/2000 — Article 5(8) of Regulation No 141/2000 — Obligation to state reasons)

Maintenance EN

Please note that this website will be undergoing technical maintenance between 28 and 31 August. Consequently, users may experience instabilities and limited functionality. We apologise for the inconvenience.

Web Content Display (Global)

Publication Detail Actions Portlet


Publication Detail Portlet

Publication detail


Pop up window annotations

Publication Viewer

Document viewer